ProfileGDS4814 / ILMN_1714393
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 75% 76% 73% 77% 76% 76% 75% 75% 77% 76% 76% 76% 74% 74% 75% 72% 74% 75% 77% 75% 79% 76% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)97.290375
GSM780708Untreated after 4 days (C2_1)102.40676
GSM780709Untreated after 4 days (C3_1)84.036373
GSM780719Untreated after 4 days (C1_2)110.50177
GSM780720Untreated after 4 days (C2_2)102.40676
GSM780721Untreated after 4 days (C3_2)103.49676
GSM780710Trastuzumab treated after 4 days (T1_1)98.368975
GSM780711Trastuzumab treated after 4 days (T2_1)98.462275
GSM780712Trastuzumab treated after 4 days (T3_1)110.90277
GSM780722Trastuzumab treated after 4 days (T1_2)104.90676
GSM780723Trastuzumab treated after 4 days (T2_2)104.79776
GSM780724Trastuzumab treated after 4 days (T3_2)102.63776
GSM780713Pertuzumab treated after 4 days (P1_1)90.870574
GSM780714Pertuzumab treated after 4 days (P2_1)94.750774
GSM780715Pertuzumab treated after 4 days (P3_1)101.2375
GSM780725Pertuzumab treated after 4 days (P1_2)79.274972
GSM780726Pertuzumab treated after 4 days (P2_2)93.221574
GSM780727Pertuzumab treated after 4 days (P3_2)101.20475
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)110.51777
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)100.40775
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)127.88179
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)103.41676
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)92.756674